Segment and Geographical Information

3 Months Ended

Dec. 31, 2018

14. Segment and Geographical Information

The Company’s management evaluates performance and allocates resources based on reported results for two reportable segments, as follows: (1) the Medical Device unit, which is comprised of manufacturing balloons and catheters used for a variety of interventional cardiology, peripheral and other applications, surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device, with end markets that include coronary, peripheral, and neurovascular, and urology, among others, and (2) the In Vitro Diagnostics unit, which consists of component products and technologies for diagnostic immunoassay as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, antigens and surface coatings.

The tables below present segment revenue, operating income (loss) and depreciation and amortization, as follows:

	Three Months Ended
	December 31,
(Dollars in thousands)	2018			2017
Revenue:
Medical Device	$	17,258		$	12,774
In Vitro Diagnostics		4,983			4,239
Total revenue	$	22,241		$	17,013

Operating income (loss):
Medical Device	$	357		$	(389	)
In Vitro Diagnostics		2,455			1,670
Total segment operating income		2,812			1,281
Corporate		(2,100	)		(1,914	)
Total operating income (loss)	$	712		$	(633	)

Depreciation and amortization:
Medical Device	$	1,388		$	1,272
In Vitro Diagnostics		116			90
Corporate		252			158
Total depreciation and amortization	$	1,756		$	1,520

The Corporate category includes expenses that are not fully allocated to Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to functions, such as executive management, corporate accounting, legal, human resources and Board of Directors. Corporate may also include expenses, such as litigation, which are not specific to a segment and thus not allocated to the operating segments.

Asset information by operating segment is not presented because the Company does not provide its chief operating decision maker assets by operating segment, as the data is not readily available or significant to the decision-making process.